FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 18, 2012--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Roy D. Baynes,
MD, PhD, will join the company as Senior Vice President, Oncology
Therapeutics. In this position, Dr. Baynes will report to Norbert W.
Bischofberger, PhD, Executive Vice President, Research and Development
and Chief Scientific Officer and will have responsibility for Gilead’s
programs in oncology. Dr. Baynes will also join Gilead’s Executive
Committee.
“Roy’s appointment reflects our commitment to building a leading
oncology research and development program, and I am very pleased to
welcome him to the Gilead team,” said Dr. Bischofberger. “Roy has an
extensive background in clinical practice, academic research and in
cancer drug development. Under his leadership, we are well positioned to
advance our growing number of pipeline programs targeted at both
hematological malignancies and solid tumors.”
Dr. Baynes joins Gilead from Amgen, where he served as Vice President,
Global Development and Therapeutic Area Head Hematology Oncology. He led
the Clinical Development and Medical Affairs teams responsible for the
approval and/or launch of numerous hematology and oncology products over
the last decade. Prior to joining Amgen in 2002, Dr. Baynes was the
Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos
Cancer Institute at Wayne State University in Detroit, where he also
held the positions of Professor of Medicine, Professor of Oncology and
Director of the Bone Marrow Transplant Program.
“I’ve long admired Gilead’s scientific approach and am excited to join
the company at a time when it is rapidly building its presence in
oncology through acquisitions and innovative partnerships,” said Dr.
Baynes. “Cancer research is an incredibly challenging and evolving
field, but one with great opportunity and I look forward to working
closely with the internal team and external collaborators as we seek to
develop novel cancer therapies that address significant unmet medical
needs.”
Dr. Baynes received his medical degree and doctorate in philosophy from
the University of the Witwatersrand in South Africa, and completed his
medical training in the Department of Hematology and Oncology at
Johannesburg Hospital. He is a member or fellow of several medical
societies and has published more than 200 peer-reviewed articles and
abstracts.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Asia
Pacific.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com
or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Susan Hubbard, 650-522-5715 (Investors)Nathan
Kaiser, 650-522-1853 (Media)
